NeoGenomics, Inc. reported second-quarter 2026 results with total revenue increasing 11% year-over-year to $202 million, driven by a 14% rise in clinical revenue and 26% growth in next-generation sequencing. The company recorded GAAP net income of $2 million, including an $11 million gain on debt extinguishment, and delivered adjusted EBITDA of $14 million, up 36%. NeoGenomics raised its full-year 2026 revenue guidance to a range of $802–$806 million and adjusted EBITDA guidance to $56–$58 million. The quarter also saw the completion of a $316 million private offering of 0.75% convertible senior notes due 2032, used to repurchase approximately $276 million of existing convertible notes and $25 million in common stock. NeoGenomics operates in the healthcare diagnostics industry, providing oncology testing and precision medicine solutions.
